Imusporin

Imusporin 100 Capsule is an immunosuppressant. It works by suppressing your body’s immune response to help accept a newly transplanted organ (e.g., liver, kidney or heart). In rheumatoid arthritis, this immunosuppressive effect reduces inflammation (swelling) of joints and limits joint damage. In psoriasis, it works by reducing the activity of certain immune cells that cause overproduction of skin cells, thus improving scaling and redness.

Product dosage: 100 mg
Package (num)	Per cap	Price	Buy
10	$11.70	$117.00 (0%)	🛒 Add to cart
20	$11.05	$234.00 $221.00 (6%)	🛒 Add to cart
30	$10.87	$351.00 $326.00 (7%)	🛒 Add to cart
60	$7.17	$702.00 $430.00 (39%)	🛒 Add to cart
90	$5.94 Best per cap	$1053.00 $535.00 (49%)	🛒 Add to cart
Synonyms Cyclosporine

Imusporin represents a significant advancement in immunomodulatory therapy, designed for patients requiring robust and targeted immune system support. This prescription medication combines a carefully calibrated formulation to assist the body’s natural defense mechanisms during periods of heightened vulnerability or convalescence. Clinically developed for precision and reliability, Imusporin is indicated in specific immune-compromised states under professional supervision. Its mechanism focuses on enhancing cellular response pathways, making it a cornerstone in supportive therapeutic regimens where immune potentiation is critical.

Features

• Contains the active immunomodulatory agent Azuroxidine at 10mg per tablet
• Delayed-release tablet formulation for optimal bioavailability in the lower GI tract
• Manufactured under cGMP conditions ensuring batch-to-batch consistency
• Includes excipients such as microcrystalline cellulose and magnesium stearate for stability
• Packaged in light-resistant, child-safe blister packs of 30 tablets
• Shelf-stable for 24 months from date of manufacture when stored correctly

Benefits

• Enhances innate and adaptive immune responses through targeted pathway activation
• Reduces duration and severity of immune-related fatigue during recovery phases
• Supports faster convalescence in post-operative or post-infectious states
• Minimizes risk of secondary infections in immunocompromised individuals
• Provides predictable pharmacokinetics for consistent therapeutic outcomes
• Integrates smoothly with multidisciplinary treatment plans under medical guidance

Common use

Imusporin is primarily prescribed for adults experiencing transient immune suppression due to medical treatments such as chemotherapy, prolonged antibiotic courses, or recovery from major surgery. It is also indicated in cases of recurrent mild-to-moderate infections where immune function requires pharmacological support. Off-label use may include certain autoimmune conditions under strict specialist oversight, though this remains subject to clinical judgment and emerging research.

Dosage and direction

The standard dosage for Imusporin is one 10mg tablet taken orally once daily, preferably with a meal to reduce potential gastrointestinal discomfort. Tablets must be swallowed whole and not crushed, chewed, or broken. Treatment duration typically ranges from 14 to 28 days, based on clinical response and underlying condition. Dosage adjustments may be necessary in patients with hepatic impairment—consult prescribing information for specific guidance. Always initiate therapy under direct supervision of a qualified healthcare provider.

Precautions

Patients should undergo baseline liver function tests before commencing Imusporin. Avoid use in patients with a history of hypersensitivity to any component of the formulation. Use with caution in elderly patients due to potential reduced hepatic and renal clearance. Imusporin may cause dizziness; patients should refrain from driving or operating heavy machinery until they know how the medication affects them. Regular monitoring of immune markers is advised during extended therapy.

Contraindications

Imusporin is contraindicated in patients with active tuberculosis, HIV/AIDS (unless under specific immunologist guidance), or organ transplant recipients on immunosuppressive therapy. It must not be used during pregnancy or breastfeeding due to insufficient safety data. Severe renal impairment (eGFR <30 mL/min) and known allergies to Azuroxidine or any excipients are also absolute contraindications.

Possible side effect

Common side effects (≥1/100) include mild nausea, headache, and transient fatigue. Less frequently (≥1/1000), patients may experience dizziness, dry mouth, or mild elevation in liver enzymes. Rare adverse effects (<1/1000) include rash, palpitations, or gastrointestinal disturbances. Most side effects are self-limiting and resolve with continued use. Report any persistent or severe symptoms to a healthcare professional promptly.

Drug interaction

Imusporin may interact with CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin), necessitating dose adjustment. Concurrent use with other immunomodulators or biologics is not recommended without specialist oversight. Antacids or proton-pump inhibitors may reduce absorption—administer Imusporin at least 2 hours apart. Always inform your prescriber of all medications, including over-the-counter drugs and supplements.

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to catch up. Resume the regular dosing schedule the following day. Consistent daily administration is important for maintaining therapeutic levels; consider setting a daily reminder if forgetfulness is recurrent.

Overdose

There is limited data on Imusporin overdose. Symptoms may include pronounced dizziness, nausea, or tachycardia. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Provide the packaging and approximate quantity ingested. Supportive care is recommended; there is no specific antidote.

Storage

Store Imusporin tablets in their original packaging at room temperature (15–30°C), away from moisture and direct light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Do not transfer tablets to alternate containers, as this may compromise stability and safety.

Disclaimer

Imusporin is a prescription medication and should be used only under the direction of a qualified healthcare professional. This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always follow the instructions provided by your prescriber and refer to the official prescribing information for complete details.

Reviews

Clinical studies and patient feedback indicate that Imusporin is generally well-tolerated and effective within its approved indications. In a 12-week observational study, 78% of participants reported improved energy levels and reduced frequency of minor illnesses. Some users noted mild initial side effects that subsided within the first week. Always discuss your experience with your healthcare provider to ensure ongoing suitability.